<DOC>
	<DOC>NCT01214720</DOC>
	<brief_summary>This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; metastatic pancreatic cancer (adenocarcinoma); good liver, kidney, and bone marrow function. previous systemic treatment for metastatic pancreatic cancer; pregnant or lactating females; fertile men, or women of childbearing potential, not using adequate contraception; major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start; current or recent treatment (within 30 days prior to starting study treatment) with another investigational drug, or participation in another investigational study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>